An ongoing dialogue on HIV/AIDS, infectious diseases,
December 11th, 2016
You Want Guidelines? We Got Guidelines!
About a million years ago — in other words, probably sometime during my ID fellowship — I asked transplant ID guru Bob Rubin how various ID guidelines came together, including one on antifungal therapy he had just led. “You lock a bunch of experts in a hotel conference room,” he said. “Provide them plenty of food and coffee. […]
February 10th, 2012
Boceprevir – PI Interaction: A “Dear Doctor” Letter We Didn’t Want To Get
By now I’m sure that most of you ID folks out there have received the following letter from Merck, the makers of boceprevir: URGENT — IMPORTANT DRUG WARNING: VICTRELIS (BOCEPREVIR) The purpose of this communication is to inform you of recent pharmacokinetic study results evaluating drug interactions between VICTRELIS, an oral chronic hepatitis C virus (HCV) NS3/4A […]
February 14th, 2011
Pspring Training Pseudomonads
A few ID/HIV issues to ponder as we welcome back the most important sport in the universe: Interesting new Guidelines on UTIs from IDSA — especially their recommendations not to use fluoroquinolones for uncomplicated cystitis and to promote nitrofurantoin for 5 days to first-line for this indication. And welcome to fosfomycin — though this could eliminate one […]
October 31st, 2009
Would Changing Restrictive HIV Testing Laws Improve Survival?
Emphatically yes — to the tune of >600,000* years of life gained nationwide. So says a nifty paper being presented at the annual IDSA meeting today by Mike April, under the direction of Rochelle Walensky. (*Original abstract said 549,437, cited in the link; number at the actual presentation, though, was 609,656.) Bottom line is that laws that […]
August 5th, 2009
Just Out: Primary Care HIV Guidelines
Over on the CID web site, they have the revised version of the “IDSA Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus”. It’s a great document, filled with useful references and a particularly strong table where to find other consensus guidelines (diabetes, hyperlipidemia, mental health, others). My vote for what will […]
December 23rd, 2008
Flu Resistance to Oseltamivir: The Bugs Win Again
I must admit, the recent report that 49 of the 50 H1N1 flu viruses tested by the CDC are resistant to oseltamivir caught me by surprise. For the non-math majors among the readership, that’s a 98% resistance rate. Yikes. Actually, the rate of resistance is so high that at first I didn’t believe it when my wife […]
November 2nd, 2008
The Big HIV News from ICAAC/IDSA
Tons of interesting stuff at this year’s combined ICAAC/IDSA meeting, most of it in non-HIV related Infectious Diseases. In aggregate, literally hundreds of posters, presentations, and symposia on MRSA, C diff, osteomyelitis, complicated UTIs, hospital-acquired pneumonia, antibiotic resistance … It’s a great meeting to catch up on general ID, and the literature review sessions alone […]
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
NEJM Journal Watch — Recent Infectious Disease Articles- When it Comes to Antimicrobial Stewardship, Is a Boost Better Than a Nudge?
- HIV Prevention and Treatment: Updated Recommendations from the International AIDS Society–USA
- Observations from ID and Beyond: Dr. Thomas O'Brien — Expert in Antimicrobial Resistance and Giant in His Field (Literally)
- How Serious Is Artemisinin Partial Resistance in African Malaria Parasites?
- Observations from ID and Beyond: Who's Going to Get Lenacapavir for HIV Prevention?